
Patients with post-operative Crohn’s disease are difficult to manage due to their risk of experiencing a more severe course, multiple symptom confounders and poor sensitivity of symptomatic remission to rule out intestinal inflammation. In this group, data are lacking on biologic therapeutic efficacy and recommendations are lacking for those with multiple medication failures. Novel non-invasive testing can simultaneously exclude alternate causes of symptoms (serum C4, fecal fat,
Like
Save
Share